Background: The pilosebaceous unit is affected by acne vulgaris (AV), which manifests as open and closed comedones, papules, pustules, and nodules, and variable degrees of scarring. Adolescent onset is the norm for AV, which is otherwise a very rare disorder. Reevaluation of pharmaceutical treatments is suggested after 8 weeks for mostly comedonal or moderate inflammatory acne and 12 weeks for severe disease. Objective: Review of new management lines of acne vulgaris. Methods: We scoured scholarly papers and databases including PubMed, Google Scholar, and Science Direct for information on acne vulgaris and management lines. Between January 2001 and November 2022, however, only the latest or most comprehensive study was considered. The authors also assessed the usefulness of references taken from similar books. Documents written in languages other than English have been overlooked because of a lack of funding to translate them. Unpublished articles, oral talks, conference abstracts, and dissertations were all generally agreed upon to not constitute valid scientific investigation. Conclusion: New therapy approaches and numerous permutations and combinations have been developed as a result of a deeper comprehension of the aetiology of acne. Benzoyl peroxide, antibiotics, retinoids, and other topical medications are the backbone of treatment. They can be administered in any combination. Oral antibiotics, hormone therapy, and isotretinoin are considered examples of systemic options of treatment, although the best option will vary from patient to patient.